[HTML][HTML] Interim FDG-PET analysis to identify patients with aggressive non-Hodgkin lymphoma who benefit from treatment intensification: a post-hoc analysis of the …
R Seifert, D Kersting, C Rischpler, P Sandach… - Leukemia, 2022 - nature.com
The randomized PETAL trial failed to demonstrate a benefit of interim FDG-PET (iPET)-
based treatment intensification over continued standard therapy with CHOP (plus rituximab …
based treatment intensification over continued standard therapy with CHOP (plus rituximab …
Interim FDG-PET analysis to identify patients with aggressive non-Hodgkin lymphoma who benefit from treatment intensification: a post-hoc analysis of the PETAL trial
R Seifert, D Kersting, C Rischpler, P Sandach… - 2022 - pubmed.ncbi.nlm.nih.gov
The randomized PETAL trial failed to demonstrate a benefit of interim FDG-PET (iPET)-
based treatment intensification over continued standard therapy with CHOP (plus rituximab …
based treatment intensification over continued standard therapy with CHOP (plus rituximab …
[HTML][HTML] Interim FDG-PET analysis to identify patients with aggressive non-Hodgkin lymphoma who benefit from treatment intensification: a post-hoc analysis of the …
R Seifert, D Kersting, C Rischpler, P Sandach… - Leukemia, 2022 - ncbi.nlm.nih.gov
The randomized PETAL trial failed to demonstrate a benefit of interim FDG-PET (iPET)-
based treatment intensification over continued standard therapy with CHOP (plus rituximab …
based treatment intensification over continued standard therapy with CHOP (plus rituximab …
Interim FDG-PET analysis to identify patients with aggressive non-Hodgkin lymphoma who benefit from treatment intensification: a post-hoc analysis of the PETAL trial.
R Seifert, D Kersting, C Rischpler, P Sandach… - Leukemia, 2022 - europepmc.org
The randomized PETAL trial failed to demonstrate a benefit of interim FDG-PET (iPET)-
based treatment intensification over continued standard therapy with CHOP (plus rituximab …
based treatment intensification over continued standard therapy with CHOP (plus rituximab …
Interim FDG-PET analysis to identify patients with aggressive non-Hodgkin lymphoma who benefit from treatment intensification: a post-hoc analysis of the PETAL trial
R Seifert, D Kersting, C Rischpler, P Sandach… - Leukemia - kups.ub.uni-koeln.de
The randomized PETAL trial failed to demonstrate a benefit of interim FDG-PET (iPET)-
based treatment intensification over continued standard therapy with CHOP (plus rituximab …
based treatment intensification over continued standard therapy with CHOP (plus rituximab …